Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus twice-daily insulin detemir in basal-bolus therapy for type 1 diabetes
2005-001522-88Phase 4Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of insulin detemir in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Mean HbA1c after 4 months of insulin detemir treatment. Started Sep 2005; status: completed.
02
Drugs
insulin detemir
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2005-001522-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001522-88.